caa a22 4500 465737889 CHVBK 20180323111800.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF02253716 doi (NATIONALLICENCE)springer-10.1007/BF02253716 Aniracetam tested in chronic psychosyndrome after long-term exposure to organic solvents [Elektronische Daten] A randomized, double-blind, placebo-controlled cross-over study with neuropsychological tests [F. Somnier, M. Østergaard, G. Boysen, P. Bruhn, B. Mikkelsen] In order to examine if the nootropic drug, aniracetam, was capable of improving cognitive performance, 44 subjects suffering from chronic psychosyndrome after long-term exposure to organic solvents were included in a randomized, double-blind, placebo-controlled, cross-over study. The treatment periods were 3 months with aniracetam 1 g daily and 3 months with placebo. Neuropsychological tests as well as a physical and neurological examination were performed at entry into the study and after each treatment period, together with an evaluation of the subjects' overall condition. Neither the doctors' nor the subjects' own assessment of the overall condition indicated that the trial medication had had any effect. No significant changes in neuropsychological symptoms were observed. A statistically significant difference in favour of aniracetam was found in only 1 of the 19 neuropsychological test measures, namely a test for constructional ability. However, in another test on visuo-spatial function, a statistically significant result was found in favour of placebo. Thus, aniracetam was found to be ineffective in the treatment of subjects suffering from chronic psychosyndrome after long-term exposure to organic solvents. Springer-Verlag, 1990 Nootropic drugs nationallicence Aniracetam nationallicence Organic solvents nationallicence Organic psychosyndrome nationallicence Cognitive functions nationallicence Neuropsychological tests nationallicence Somnier F. Department of Neurology, Rigshospitalet University Hospital, DK-2100, Copenhagen, Denmark aut Østergaard M. Department of Neurology, Rigshospitalet University Hospital, DK-2100, Copenhagen, Denmark aut Boysen G. Department of Neurology, Rigshospitalet University Hospital, DK-2100, Copenhagen, Denmark aut Bruhn P. Department of Neurology, Rigshospitalet University Hospital, DK-2100, Copenhagen, Denmark aut Mikkelsen B. Department of International Clinical Research, Roche A/S, DK-2650, Hvidovre, Denmark aut Psychopharmacology Springer-Verlag 101/1(1990-05-01), 43-46 0033-3158 101:1<43 1990 101 213 https://doi.org/10.1007/BF02253716 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02253716 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Somnier F. Department of Neurology, Rigshospitalet University Hospital, DK-2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Østergaard M. Department of Neurology, Rigshospitalet University Hospital, DK-2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Boysen G. Department of Neurology, Rigshospitalet University Hospital, DK-2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Bruhn P. Department of Neurology, Rigshospitalet University Hospital, DK-2100, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Mikkelsen B. Department of International Clinical Research, Roche A/S, DK-2650, Hvidovre, Denmark aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 101/1(1990-05-01), 43-46 0033-3158 101:1<43 1990 101 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer